

4.67  
3.38 3.28

# Frontiers in Natural Product Chemistry



Editor:  
Atta-ur-Rahman, *FRS*



**Bentham Books**

# Frontiers in Natural Product Chemistry

*(Volume 7)*

Edited by

**Atta-ur-Rahman, *FRS***

*Kings College*

*University of Cambridge*

*Cambridge*

*UK*

## **Frontiers in Natural Product Chemistry**

*(Volume 7)*

Editors: Prof. Atta-ur-Rahman, *FRS*

ISSN (Online): 2212-3997

ISSN (Print): 1574-0897

ISBN (Online): 978-1-68108-916-4

ISBN (Print): 978-1-68108-917-1

ISBN (Paperback): 978-1-68108-918-8

©2021, Bentham Books imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

## **BENTHAM SCIENCE PUBLISHERS LTD.**

### **End User License Agreement (for non-institutional, personal use)**

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [permission@benthamscience.org](mailto:permission@benthamscience.org).

### **Usage Rules:**

1. All rights reserved: The Work is 1. the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

### ***Disclaimer:***

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

### ***Limitation of Liability:***

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

### **General:**

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

**Bentham Science Publishers Ltd.**

Executive Suite Y - 2

PO Box 7917, Saif Zone

Sharjah, U.A.E.

Email: [subscriptions@benthamscience.org](mailto:subscriptions@benthamscience.org)



## CONTENTS

PREFACE .....	i
LIST OF CONTRIBUTORS .....	ii
<b>CHAPTER 1 PLANT-DERIVED ANTICANCER COMPOUNDS USED IN CANCER THERAPIES</b> .....	1
<i>Alexander Chota, Blassan P. George and Heidi Abrahamse</i>	
<b>INTRODUCTION</b> .....	1
Current Cancer Treatment Options and Their Limitations .....	2
Origin/History of Plant-derived Agents in Cancer Therapies .....	3
Ayurvedic System of Medicine in Cancer Therapies .....	4
Plant Derived Anticancer Compounds and their Clinical Uses .....	6
The General Classification of Major Plant-derived Anticancer Compounds .....	11
<i>Alkaloids</i> .....	11
<i>Flavonoids</i> .....	11
<i>Brassinosteroids</i> .....	14
<i>Terpenoids</i> .....	14
Structures of Major Anticancer Compounds of Plant Origin .....	15
Common Anticancer Drugs of Plant Origin in Clinical Practice .....	17
General Mechanism of Action of Plant-derived Anticancer Compounds .....	19
Importance and Advantages of Anticancer Compounds of Plant Origin .....	20
<b>CONCLUSION AND FUTURE PERSPECTIVES</b> .....	20
<b>ACRONYMS</b> .....	20
<b>CONSENT FOR PUBLICATION</b> .....	21
<b>CONFLICT OF INTEREST</b> .....	21
<b>ACKNOWLEDGEMENTS</b> .....	21
<b>REFERENCES</b> .....	21
<b>CHAPTER 2 PRADIMICIN AND BENANOMICIN ANTIBIOTICS: FROM ANTIFUNGAL POLYKETIDE NATURAL PRODUCTS TO ANTIVIRAL AGENTS WITH A UNIQUE CARBOHYDRATE-BINDING MODE OF ACTION</b> .....	31
<i>Rocío Abín, Visitación López-Miranda, Ana San-Félix and Ernesto Quesada</i>	
<b>INTRODUCTION</b> .....	32
<b>DISCOVERY, STRUCTURAL CHARACTERISATION AND CHEMICAL MODIFICATIONS</b> .....	32
<b>BIOLOGICAL ACTIVITIES</b> .....	56
Antifungal Activity .....	57
Antiviral Activity .....	60
Other Activities: Antibacterial, Antitumoral .....	63
<b>MECHANISM OF ACTION OF BPAS</b> .....	64
A Unique Mechanism of Action: Calcium-Dependent Mannose Binding .....	64
Carbohydrate-binding Agents (CBAs): Glycans of HIV as Therapeutic Targets .....	71
Apoptosis .....	72
Biosynthesis of BPAs: Tailoring Polyketides .....	74
Total Synthesis of BPAs .....	79
<b>CONCLUDING REMARKS</b> .....	94
<b>CONSENT FOR PUBLICATION</b> .....	95
<b>CONFLICT OF INTEREST</b> .....	95
<b>ACKNOWLEDGEMENTS</b> .....	95
<b>REFERENCES</b> .....	95
<b>CHAPTER 3 THE CHEMICAL COMPOSITIONS OF BIXA ORELLANA AND THEIR PHARMACOLOGICAL ACTIVITIES</b> .....	110

*Carlos A. Méndez-Cuesta, Fernando Rodríguez-Ramos, Cuauhtémoc Pérez-González,  
Julia Pérez-Ramos and Salud Pérez-Gutiérrez*

<b>INTRODUCTION</b> .....	110
<b>USE IN TRADITIONAL MEDICINE</b> .....	112
<b>PHYTOCHEMISTRY</b> .....	112
<b>ANTIMICROBIAL ACTIVITY</b> .....	114
<b>ANTIPARASITIC ACTIVITY</b> .....	118
<b>ANTI-INFLAMMATORY EFFECTS</b> .....	119
<b>HYPOGLYCEMIC EFFECTS</b> .....	120
<b>METABOLIC SYNDROME</b> .....	121
<b>CYTOTOXIC ACTIVITY</b> .....	123
<b>ANTIOXIDANT ACTIVITY</b> .....	124
<b>HEPATOPROTECTIVE ACTIVITY</b> .....	128
<b>BRONCHODILATOR EFFECTS</b> .....	128
<b>DIURETIC EFFECTS</b> .....	129
<b>DISCUSSION AND CONCLUSION</b> .....	129
<b>CONSENT FOR PUBLICATION</b> .....	129
<b>CONFLICT OF INTEREST</b> .....	130
<b>ACKNOWLEDGEMENTS</b> .....	130
<b>LIST OF ABBREVIATIONS</b> .....	130
<b>REFERENCES</b> .....	131
<b>CHAPTER 4 OVERVIEW OF PHYTOCHEMISTRY AND PHARMACOLOGY OF NILAKANTHI (AJUGA BRACTEOSA WALL. EX BENTH.)</b> .....	139
<i>Apurba Gohain, Debanga Sourav Saikia, Sangita Baruah, Ashoke Kumar Das and Ajay Sharma</i>	
<b>INTRODUCTION</b> .....	140
<b>BOTANICAL DESCRIPTION</b> .....	142
<b>MORPHOLOGY</b> .....	142
<b>TRADITIONAL USES</b> .....	143
<b>MODERN USES</b> .....	144
<b>PROBABLE METHODS OF CULTIVATION</b> .....	144
<b>STATUS AND METHOD OF CONSERVATION</b> .....	145
<b>PHYTOCHEMICAL COMPOSITION</b> .....	146
<b>PHARMACOLOGICAL ACTIVITY</b> .....	146
<b>ANTICANCER</b> .....	149
<b>ANTI-INFLAMMATORY</b> .....	150
<b>ANTI-DIABETIC</b> .....	150
<b>ANTI-ANALGESICS</b> .....	150
<b>ANTIOXIDANT</b> .....	150
<b>OTHER ACTIVITIES</b> .....	151
<b>GREEN SYNTHESIS OF METAL NANOPARTICLES</b> .....	151
<b>CONCLUSION</b> .....	152
<b>CONSENT FOR PUBLICATION</b> .....	153
<b>CONFLICT OF INTEREST</b> .....	153
<b>ACKNOWLEDGEMENTS</b> .....	153
<b>REFERENCES</b> .....	153
<b>CHAPTER 5 TETRACYCLIC BENZOCARBAZOLES AND DERIVATIVES: SYNTHESIS AND APPLICATIONS</b> .....	158
<i>Francisco Vilaça Gaspar, Joseane Alves Mendes, Paulo Roberto Ribeiro Costa, Miguel Yus, Francisco Foubelo and Camilla Djenne Buarque</i>	

<b>INTRODUCTION</b> .....	158
Early Methodologies and Modern [3, 3]-sigmatropic Rearrangement .....	159
Disconnections Using Aniline and Tetralones or Indenones Derivatives .....	163
Disconnections Using o-iodo-N-(arylsulfonyl)anilines and Dihydronaphthalenes or Indenes Derivatives .....	164
Disconnections Employing Indol Derivatives .....	168
Asymmetric Synthesis Employing Chiral N-tert-butanesulfinyl Imines .....	177
Disconnections Employing 2H-chromen-2-ones and Analogs .....	179
Aza-Coumestans and Derivatives .....	182
Cross-coupling Reactions .....	185
<b>CONCLUDING REMARKS</b> .....	189
<b>CONSENT FOR PUBLICATION</b> .....	190
<b>CONFLICT OF INTEREST</b> .....	190
<b>ACKNOWLEDGEMENTS</b> .....	190
<b>REFERENCES</b> .....	190
<b>CHAPTER 6 CHALCONES AS ANTI-INFLAMMATORY, ANTI-DIABETIC, AND ANTI-DEPRESSANT AGENTS</b> .....	197
<i>Begum Evranos Aksoz</i>	
<b>INTRODUCTION</b> .....	197
<b>ANTI-INFLAMMATORY CHALCONES</b> .....	198
Anti-inflammatory Targets for Chalcones .....	198
<i>Heme Oxygenase-1</i> .....	199
<i>Nuclear Factor-<math>\kappa</math>B and Histone Deacetylases</i> .....	199
<i>Kinases and Activator Protein-1</i> .....	199
<i>Toll-like Receptor 4 and Myeloid Differentiation 2 Accessory Molecule</i> .....	200
<i>Cyclooxygenase and 5-Lipoxygenase</i> .....	200
<i>Nitric Oxide</i> .....	200
<i>Tumour Necrosis Factor-Alpha, Intercellular Adhesion Molecule-1, and Vascular Cell Adhesion Molecule-1</i> .....	201
<i>Monocyte Chemoattractant Protein-1</i> .....	201
<i>Interleukins</i> .....	201
Natural Anti-inflammatory Chalcones .....	202
Synthesized Anti-inflammatory Chalcones .....	211
<b>ANTIDIABETIC CHALCONES</b> .....	217
Antidiabetic Targets for Chalcones .....	217
<i>Sodium Glucose Cotransporter 2</i> .....	217
<i>Glucose Transporter Type 4</i> .....	217
<i>Adenosine Monophosphate Activated Protein Kinase</i> .....	217
<i>Peroxisome Proliferator-Activated Receptor Gamma</i> .....	218
<i><math>\alpha</math>-Glucosidase</i> .....	218
<i>Dipeptidyl Peptidase-IV</i> .....	218
<i>Protein Tyrosine Phosphatase 1B</i> .....	218
<i>Aldose Reductase</i> .....	218
Natural Antidiabetic Chalcones .....	219
Synthesized Antidiabetic Chalcones .....	223
<b>ANTIDEPRESSANT CHALCONES</b> .....	226
Antidepressant Targets for Chalcones .....	226
5-Hydroxytryptamine .....	227
<i>Norepinephrine (NE)</i> .....	227
<i>Monoamine Oxidase</i> .....	227



Natural Antidepressant Chalcones .....	227
Synthesized Antidepressant Chalcones .....	228
<b>CRITICAL ASSESSMENT AND DISCUSSION .....</b>	<b>234</b>
<b>CONCLUDING REMARKS .....</b>	<b>234</b>
<b>CONSENT FOR PUBLICATION .....</b>	<b>235</b>
<b>CONFLICT OF INTEREST .....</b>	<b>235</b>
<b>ACKNOWLEDGEMENTS .....</b>	<b>235</b>
<b>REFERENCES .....</b>	<b>235</b>
<b>CHAPTER 7 BIOACTIVE STEROIDS FROM MARINE ORGANISMS .....</b>	<b>247</b>
<i>Marina P. Savić, Marija N. Sakač and Jovana. J. Ajduković</i>	
<b>INTRODUCTION .....</b>	<b>247</b>
<b>BIOACTIVE STEROIDS FROM MARINE SPONGES .....</b>	<b>248</b>
A-Norsteroids .....	249
Steroid Alkaloids .....	250
Pregnane Steroids .....	251
Oxygenated Steroids .....	252
<i>Dioles and Trioles .....</i>	<i>253</i>
<i>Polyhydroxylated Steroids .....</i>	<i>256</i>
<i>Epoxysterols .....</i>	<i>259</i>
<i>Epidioxysterols .....</i>	<i>260</i>
Steroid Sulfates .....	261
<i>Steroid Monosulfates .....</i>	<i>261</i>
<i>Steroid Polysulfates .....</i>	<i>262</i>
<i>Sulfated Steroid Dimers .....</i>	<i>264</i>
<i>Sulfated Amino-acid Conjugates .....</i>	<i>265</i>
<i>Secosteroids .....</i>	<i>265</i>
<i>Polyacetylated Sterols .....</i>	<i>266</i>
<i>Keto Steroids .....</i>	<i>267</i>
<i>Steroid Esters .....</i>	<i>270</i>
<i>Steroid Glycosides .....</i>	<i>270</i>
<i>Methylene steroids .....</i>	<i>274</i>
<i>4-Methylene Sterols with Rearranged 6/6/5/7 Ring System .....</i>	<i>278</i>
<i>4-Methylene Secosterols .....</i>	<i>279</i>
Sterols with a Cyclopropane Ring at C-25 and C-26 .....	280
Others .....	282
<i>Phenanthrene Steroid Derivatives .....</i>	<i>282</i>
<i>Steroid Derivatives with Bicyclo [4.3.1] A/B Ring .....</i>	<i>283</i>
<b>BIOACTIVE STEROIDS FROM MARINE MACROALGAE .....</b>	<b>283</b>
<b>BIOACTIVE STEROIDS FROM MARINE CUCUMBERS .....</b>	<b>292</b>
Triterpene $\Delta^7$ Glycosides .....	293
Triterpene $\Delta^9(11)$ Glycosides .....	301
Triterpene $\Delta^8$ and Spyro Glycosides .....	308
<b>CONCLUSION .....</b>	<b>309</b>
<b>CONSENT FOR PUBLICATION .....</b>	<b>312</b>
<b>CONFLICT OF INTEREST .....</b>	<b>312</b>
<b>ACKNOWLEDGEMENTS .....</b>	<b>312</b>
<b>REFERENCES .....</b>	<b>312</b>
<b>SUBJECT INDEX .....</b>	<b>552</b>

## PREFACE

*Frontiers in Natural Product Chemistry* presents recent advances in the chemistry and biochemistry of naturally occurring compounds. The book is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information on bioactive natural products. The chapters in this volume are written by eminent authorities in the field.

In Chapter 1, Abrahamse *et al* present the progress made in the field of plant-derived anticancer agents in the treatment of cancer, as well as their mechanism of action and the limitations associated with current therapeutic options. Ernesto *et al.*, in the second chapter of the book, have reviewed benanomycin-pradimicin antibiotics (BPAs) with respect to structural, functional, mechanistic and synthetic aspects. Chapter 3 by Pérez-Gutiérrez *et al* provides interesting information regarding the numerous pharmacological activities of the different parts and extracts of *Bixa Orellana*.

Chapter 4 of the book by Sharma *et al* focuses on the distribution, cultivation, traditional uses, phytochemistry, pharmacological potential and future prospective of *Nilakanthi* (*Ajuga bracteosa* Wall. ex Benth.). Buarque *et al.*, in chapter 5, discuss the synthesis of benzocarbazoles, mostly benzo[a]carbazoles (including the dihydro and tetrahydro derivatives), with interesting properties. Chapter 6 of the book by Aksoz deals with the anti-inflammatory, anti-diabetic, and anti-depressant activities of chalcones. In the last chapter by Ajduković, an overview of the new steroid compounds isolated from marine sponges, macroalgae and cucumbers, is presented.

I hope that the readers will find these reviews valuable and thought-provoking so that they may trigger further research in the quest for new and novel natural therapies against various diseases. I am grateful for the timely efforts made by the editorial personnel, especially Mr. Mahmood Alam (Director Publications), and Miss Asma Ahmed (Senior Manager Publications) at Bentham Science Publishers in bringing this volume to fruition.

**Atta-ur-Rahman, FRS**  
Kings College  
University of Cambridge  
Cambridge  
UK

## List of Contributors

- Alexander Chota** Laser Research Centre, Faculty of Health Sciences, University of Johannesburg, P.O. Box 17011, Doornfontein 2028, South Africa
- Ana San-Félix** Instituto de Química Médica (IQM), Dpt. of Biomimetics for Drug Discovery, Agencia Estatal Consejo Superior de Investigaciones Científicas (AE-CSIC), Madrid, Spain
- Apurba Gohain** Department of Chemistry, Assam University Silchar, Dorgakona, Silchar, Assam, India
- Ashoke Kumar Das** Department of Botany, Abhayapuri College, Abhayapuri, Srijangram, Assam, India
- Ajay Sharma** Department of Chemistry, Chandigarh University, NH-95, Chandigarh-Ludhiana Highway, Gharuan, Mohali, Punjab, India
- Begum Evranos Aksoz** Suleyman Demirel University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 32000, Isparta, Turkey
- Blassan P. George** Laser Research Centre, Faculty of Health Sciences, University of Johannesburg, P.O. Box 17011, Doornfontein 2028, South Africa
- Carlos A. Méndez-Cuesta** Universidad Autónoma Metropolitana, Unidad Xochimilco, Calzada del Hueso 1100, Mexico City, 04960, Mexico
- Cuauhtémoc Pérez-González** Universidad Autónoma Metropolitana, Unidad Xochimilco, Calzada del Hueso 1100, Mexico City, 04960, Mexico
- Camilla Djenne Buarque** Department of Chemistry, Pontifical Catholic University of Rio de Janeiro Puc-Rio, CEP 22435-900 Rio de Janeiro, Brazil
- Debanga Sourav Saikia** Department of Chemistry, Assam University Silchar, Dorgakona, Silchar, Assam, India
- Ernesto Quesada** Instituto de Química Médica (IQM), Dpt. of Biomimetics for Drug Discovery, Agencia Estatal Consejo Superior de Investigaciones Científicas (AE-CSIC), Madrid, Spain  
Unidad Asociada I+D+i Instituto de Química Médica (IQM-CSIC), Facultad de Ciencias de la Salud (URJC), Madrid, Spain
- Francisco Vilaça Gaspar** Laboratory of Bioorganic Chemistry, Nucleus of Research of Natural Products, Health Science Center, Federal University of Rio de Janeiro UFRJ, CEP 21941-590, Rio de Janeiro, Brazil
- Francisco Foubelo** Laboratory of Bioorganic Chemistry, Nucleus of Research of Natural Products, Health Science Center, Federal University of Rio de Janeiro UFRJ, CEP 21941-590, Rio de Janeiro, Brazil
- Fernando Rodríguez-Ramos** Universidad Autónoma Metropolitana, Unidad Xochimilco, Calzada del Hueso 1100, Mexico City, 04960, Mexico
- Heidi Abrahamse** Laser Research Centre, Faculty of Health Sciences, University of Johannesburg, P.O. Box 17011, Doornfontein 2028, South Africa
- Joseane Alves Mendes** Departamento de Química Orgânica, Instituto de Síntese Orgânica, and Centro de Innovacion en Química Avanzada (ORFEO –CINQA), Universidad de Alicante, Apdo. 99, 03080 Alicante, Brazil

- Jovana J. Ajduković** Department of Chemistry, Biochemistry and Environmental Protection, Faculty of Sciences, University of Novi Sad, Trg Dositeja Obradovića 3, 21000, Novi Sad, Serbia
- Julia Pérez-Ramos** Universidad Autónoma Metropolitana, Unidad Xochimilco, Calzada del Hueso 1100, Mexico City, 04960, Mexico
- Marina P. Savić** Department of Chemistry, Biochemistry and Environmental Protection, Faculty of Sciences, University of Novi Sad, Trg Dositeja Obradovića 3, 21000, Novi Sad, Serbia
- Marija N. Sakač** Department of Chemistry, Biochemistry and Environmental Protection, Faculty of Sciences, University of Novi Sad, Trg Dositeja Obradovića 3, 21000, Novi Sad, Serbia
- Miguel Yus** Departamento de Química Orgánica, Instituto de Síntesis Orgánica, and Centro de Innovación en Química Avanzada (ORFEO –CINQA), Universidad de Alicante, Apdo. 99, 03080 Alicante, Brazil
- Paulo Roberto Ribeiro Costa** Laboratory of Bioorganic Chemistry, Nucleus of Research of Natural Products, Health Science Center, Federal University of Rio de Janeiro UFRJ, CEP 21941-590, Rio de Janeiro, Brazil
- Rocío Abín** Instituto de Química Médica (IQM), Dpt. of Biomimetics for Drug Discovery, Agencia Estatal Consejo Superior de Investigaciones Científicas (AE-CSIC), Madrid, Spain
- Salud Pérez-Gutiérrez** Universidad Autónoma Metropolitana, Unidad Xochimilco, Calzada del Hueso 1100, Mexico City, 04960, Mexico
- Sangita Baruah** Department of Botany, Nowgong College, Nagaon, Assam, India
- Visitación López-Miranda** Área de Farmacología y Nutrición, Departamento de Ciencias Básicas de la Salud, Universidad Rey Juan Carlos (URJC), Alcorcón, Spain  
Unidad Asociada I+D+i Instituto de Química Médica (IQM-CSIC), Facultad de Ciencias de la Salud (URJC), Madrid, Spain

## CHAPTER 1

# Plant-Derived Anticancer Compounds Used in Cancer Therapies

Alexander Chota<sup>1</sup>, Blassan P. George<sup>1</sup> and Heidi Abrahamse<sup>1,\*</sup>

<sup>1</sup> Laser Research Centre, Faculty of Health Sciences, University of Johannesburg, P.O. Box 17011, Doornfontein 2028, South Africa

**Abstract:** Cancer is a serious public health problem that affects both men and women. Globally cancer is one of the leading causes of death. The risk factors associated with cancer development are categorized into intrinsic and extrinsic. The treatment modalities used in the treatment of cancer, such as chemotherapy, radiotherapy, surgery, and targeted therapies have adverse effects either during or after therapy. Currently, plant-derived anticancer compounds are being used in the treatment of various cancers. The variation of these compounds is according to their origin, general classification, and mechanism of action. Various studies have shown that anticancer agents of natural origin have fewer side effects when compared to traditional therapies. Anticancer agents of natural origins are a revolution in the field of cancer research and treatment as they are easy to isolate, cost-effective, and reliable to use. The advantage of anticancer agents of natural origin over synthetic ones and conventional therapeutic options is that their functions are selective and specific to a tumor undergoing treatment. This article is aimed at covering the success of plant-derived anticancer agents in the treatment of cancer, as well as their mechanism of action and the limitations associated with current therapeutic options.

**Keywords:** Ayurvedic system, Cancer, Plant-derived anticancer agents, Treatment.

## INTRODUCTION

Globally, cancer is a very serious health problem. In the United States, it has been identified as the second leading cause of death [1]. Through its metastatic abilities, cancer can spread to other parts of the body, and its incidence rate differs across geographical locations and gender [2]. In 2018, the GLOBOCAN report showed an estimated number of new cancer cases to be 18.1 million and 9.6 million cancer-related deaths [3]. In Sub-Saharan Africa (SSA), the number of

\* Corresponding author Heidi Abrahamse: Laser Research Centre, Faculty of Health Sciences, University of Johannesburg, P.O. Box 17011, Doornfontein 2028, South Africa; Tel: +27 11 559 6550; Fax: +27 11 559 6448; E-mail: habrahamse@uj.ac.za

cancer cases is expected to double in the next 20 years [4]. Out of all cancers, lung cancer has been identified as the leading cause of death among men. This is because of the arising transformational changes of normal cells into cancerous cells. The transformation of these cells is due to the interaction between genetic materials with three different categories of carcinogenic agents such as chemical, biological and physical carcinogens. These carcinogens are well known to induce mutation through activation and inactivation of various signaling pathways [5]. Breast cancer has been identified as the most frequently diagnosed type of cancer among women [2].

Various factors contribute to the development of cancer. These factors may further be divided into intrinsic and extrinsic. Intrinsic risk factors are any mutations that arise randomly. They could be inherited or be caused by random errors during replication. These types of risk factors cannot be controlled. Extrinsic risk factors are carcinogens from the environment that can cause DNA damage, leading to mutations. These risk factors are further divided into two categories; endogenous or exogenous risk factors. Extrinsic endogenous risk factors are genetic factors that are related to an individual's characteristics. These include biological aging, diet, hormones, DNA repair mechanisms, inflammation, genetic susceptibility, while extrinsic exogenous risk factors include radiation, chemicals, viruses, and smoking. Several biological and epidemiological studies have pointed out some of the exogenous risk factors such as tobacco smoking to be associated with lung cancer, ultraviolet radiation (UV) with skin cancer, and viral infections to be associated with the development of both liver and cervical cancer [6, 7]. In the following paragraphs, this review is aimed at highlighting the significance of some plant-derived anticancer compounds used in the treatment of cancer, their origin and history, mechanisms of action, current cancer treatment options, and their limitation as well as their potential application in drug development.

### **Current Cancer Treatment Options and Their Limitations**

There are various traditional modalities used in the treatment of cancer. Therapeutic options used are dependent on the type of tumor and the stage of cancer [8]. Traditional therapeutic modalities used in the treatment of cancer are divided into two classes localized and systemic therapies. Localized treatment options include; radiation therapy and surgery, while systemic options include chemotherapy, immunotherapy, gene therapy, and other targeted therapies such as clustered regularly interspaced short palindromic repeats (CRISPER) [9]. Radiotherapy (RT) is a non-invasive medical technique used in the treatment of cancer. Unlike other cancer therapies, radiotherapy uses ionizing radiation to kill tumor cells. The adverse effects associated with RT include genetic mutations,

infertility, hair loss, and the development of secondary malignancies [10]. Surgery is an invasive procedure that is used in the diagnosis and treatment of various cancers, such as breast cancer. It is often combined with other therapies such as RT and chemotherapy. The side effects experienced during or after this type of treatment include pain, bleeding, infections, and loss of organ function [11].

Chemotherapy is a type of cancer therapy that one or more anticancer drugs that target fast-growing tumor cells. It was believed that chemotherapeutic drugs were specific to targeting only cancer cells, but it is now reviewed that it can also damage normal cells leading to dose-dependent adverse effects such as hair loss, nausea, fatigue, and vomiting [12]. On the other hand, other systemic treatment approaches such as immunotherapy are the type of cancer treatment that uses components of the immune system to suppress tumor cells. There are different types of immunotherapy, among them are vaccines and monoclonal antibodies such as rituximab, trastuzumab, cetuximab, and bevacizumab [9]. Side effects related to immunotherapy do not occur immediately but are mostly observed after a few weeks of treatment, and these include fever, chills, fatigue, diarrhea, and dermatitis [13].

Gene therapy and other targeted therapies such as CRISPER involve the modification of genes to treat or prevent the spread of disease. In 1990, the first gene therapy for a patient with combined immunodeficiency disorders was approved by the Food and Drug Administration (FDA). Ever since, several clinical trials involving different approaches in gene therapy have been conducted with successful outcomes in cancers such as leukemia, lymphocytic leukemia, and brain cancers [14]. Some of the common side effects of gene therapy include inflammation and less genotoxicity which could be due to self-inactivating vectors [15]. Apart from these traditional modalities, there are novel promising therapies with good specificities, such as photodynamic therapy (PDT) [16].

### **Origin/History of Plant-derived Agents in Cancer Therapies**

For many years, medicinal plants have been used in the treatment of many diseases. African and Asian populations have consumed several plant derivatives for medicinal purposes [17]. Over 5000 years, plants have been utilized for various medicinal purposes, foods, and spices. During these olden times, medicinal plants were administered without knowing the active biochemical constituents contained within the plant and their mechanisms of action. Not only in the 18<sup>th</sup> century when Anton Von Störck conducted research that focussed on the investigation of poisons contained in some herbs. The research laid a principal baseline for clinical investigations [18, 19]. Two ancient cultures have provided current medicinal plant-related knowledge, Traditional Chinese medicine (TCM)

## CHAPTER 2

# Pradimicin and Benanomycin Antibiotics: From Antifungal Polyketide Natural Products to Antiviral Agents with a Unique Carbohydrate-Binding Mode of Action

Rocío Abín<sup>1</sup>, Visitación López-Miranda<sup>2,3</sup>, Ana San-Félix<sup>1</sup> and Ernesto Quesada<sup>1,3,\*</sup>

<sup>1</sup> Instituto de Química Médica (IQM), Department of Biomimetics for Drug Discovery, Agencia Estatal Consejo Superior de Investigaciones Científicas (AE-CSIC), Madrid, Spain

<sup>2</sup> Área de Farmacología y Nutrición, Departamento de Ciencias Básicas de la Salud, Universidad Rey Juan Carlos (URJC), Alcorcón, Spain

<sup>3</sup> Unidad Asociada I+D+i Instituto de Química Médica (IQM-CSIC), Facultad de Ciencias de la Salud (URJC), Madrid, Spain

**Abstract:** The family of benanomycin-pradimicin antibiotics (BPAs) is reviewed exhaustively with respect to its structural, functional, mechanistic and synthetic aspects. BPAs can be considered a unique class of compounds from the structural point of view due to the presence of a 5,6-dihydro-benzo[ $\alpha$ ]naphthacenequinone (DHBNQ) scaffold attached to a glycan moiety. The mechanism of action is 'lectin-like' and related to the selective recognition and binding to specific mannoside residues located at the surface of the membrane of fungal and viral pathogens. BPAs are prototype structures of non-peptidic small-size carbohydrate-binding agents (CBAs).

**Keywords:** 5,6-dihydro-benzo[ $\alpha$ ]naphthacenequinone (DHBNQ), Antibiotics, Antifungal, Antiviral, Aromatic Polyketides, Atropisomerism, Benanomycin, Benanomycin-Pradimicin Antibiotics (BPAs), Biosynthesis, Carbohydrate-Binding Agents (CBAs), Natural products, Pradimicin, Total Synthesis.

\* **Corresponding author Ernesto Quesada:** Instituto de Química Médica (IQM), Department of Biomimetics for Drug Discovery, Agencia Estatal Consejo Superior de Investigaciones Científicas (AE-CSIC), c/ Juan de la Cierva, 3. Madrid-28006, Spain; Tel: +34 915622900; Fax: +34 915644853; E-mail: EQ1@iqm.csic.es

Atta-ur-Rahman, FRS (Ed.)

All rights reserved-© 2021 Bentham Science Publishers



## INTRODUCTION

Nature is the main and irreplaceable source of bioactive compounds. The scientific community has devoted historically notable efforts to searching for naturally occurring products endowed with both original structures and interesting activities. As a result, many families of substances from diverse origins have been discovered, structurally characterised and tested as chemotherapeutics.

In the late 80s of the last century, a novel class of secondary metabolites, denominated benanomicins and pradimicins antibiotics (BPAs), emerged from screening programs searching for antifungal drugs. The BPA family currently encompasses a large number of congeners isolated from natural sources as well as many semisynthetic derivatives. They share a common structure based on a molecular construction that confers a unique mechanism of action on these compounds.

This chapter will be devoted to an exhaustive description and in-depth critical analysis from all aspects of this class of compounds. It will be organised in thematic sections focused on the isolation, structural characterisation and chemical modifications (Section 2), the biological activity (Section 3), mechanistic considerations (Section 4), and finally, will be unraveling the biosynthesis procedure and the different strategies of total chemical synthesis that have been attempted (Section 5).

## DISCOVERY, STRUCTURAL CHARACTERISATION AND CHEMICAL MODIFICATIONS

The first references regarding BPAs appeared almost simultaneously in 1988 from two different research groups. Takeuchi described benanomicin A (**1**) and B (**2**) as metabolites isolated from unspecified *Actinomyces* *sp.* bacteria related to *Actinomadura* or *Microtetraspora* (strain MH193-16F4) [1, 2]. In a parallel and independent way, Oki described pradimicins A (**3**) and B (**4**) isolated from the *Actinomyces* bacteria *Actinomadura hibisca* (strain P157-2) obtained from soil collected from Fiji [3, 4]. The structures of the first BPAs obtained by fermentation of bacterial strains are shown in Fig. (1).

The promising biological activities exhibited by these BPAs have made them valuable candidates for chemotherapeutic intervention. They are active *in vitro* and *in vivo*, protecting cell cultures and murine animal models from infections caused by fungi. Apart from exhibiting remarkable antifungal activity, **1**, **2** and **3** proved to be efficient inhibitors of the human immune deficiency virus (HIV), the causative agent of the acquired immunodeficiency syndrome (AIDS) [5, 6],

attracting amplified interest. This circumstance must be particularly emphasised due to the severe AIDS pandemic context at the time of the discovery of the first BPAs and the urgent search for antiretroviral agents to treat this fatal disease.




Fig. (1). First members of the BPA family, benanomycins A-B (1-2) and pradimicins A-C (3-5) [1 - 4].

The members of the family increased in 1989 with the incorporation of pradimicin C (5) [7, 8]. As can be observed in Fig. (1), pradimicin C has the same structure as benanomycin B(2). Although they were believed originally to be different molecules, a detailed analysis confirmed both as structurally identical. Despite this circumstance, we have preferred to list both denominations of the molecule to keep the rigour of the original description while stressing that 2 and 5 are the same compound isolated independently by different research groups and published separately. It was also speculated that pradimicin B (4) could not be a proper metabolite but a derivative obtained *in situ* by partial hydrolysis during the isolation process, although this point has never been corroborated experimentally.

The first studies on BPAs explored their chemical degradation and analysed the identity of the different fragments of the molecule (Scheme 1). Thus, pradimicin

## The Chemical Compositions of *Bixa orellana* and their Pharmacological Activities

Carlos A. Méndez-Cuesta<sup>1</sup>, Fernando Rodríguez-Ramos<sup>1</sup>, Cuauhtémoc Pérez-González<sup>1</sup>, Julia Pérez-Ramos<sup>1</sup> and Salud Pérez-Gutiérrez<sup>1,\*</sup>

<sup>1</sup> Universidad Autónoma Metropolitana, Unidad Xochimilco, Calzada del Hueso 1100, Mexico City, 04960, Mexico

**Abstract:** For many years, natural products have been exploited to obtain extracts and pure substances, especially to treat various diseases and conditions. *Bixa orellana*, the seasoning and colouring known as “Achiote”, is used in several countries in traditional medicine to treat a variety of health needs, mainly using the dried pulp of the fruit, the seeds, the leaves and the roots. The objective of this review is to provide information regarding the numerous pharmacological activities of the different parts and extracts of *B. orellana*, such as the anti-inflammatory, anti-bacterial and anti-parasitic activity, as well as the hypoglycaemic, cytotoxic, antioxidant, bronchodilator, diuretic and hepatoprotective effects. This information will promote the development of further research regarding this plant and its various benefits, either in the form of an extract or pure substance, such as bixin and norbixin. Similarly, it will allow the discovery of its various mechanisms of action for each disease, which will promote the development of new active compounds.

**Keywords:** Antimicrobial activity, Antioxidant activity, Bixin, *Bixa orellana*, Cytotoxic activity, Norbixin, Phytochemistry.

### INTRODUCTION

Throughout the years, humans have used plants to meet basic needs, such as clothing, food and medicine, among others. At the beginning of civilization, plants were employed in traditional medicine, mainly as tea, powders, tinctures and poultices [1].

The World Health Organization (WHO) has indicated that, currently, approximately 80% of the population in developing countries depends on traditional medicines for the treatment of various health problems [2], such as fever, malaria and diarrhea [3].

\* Corresponding author Salud Pérez-Gutiérrez: Universidad Autónoma Metropolitana, Unidad Xochimilco, Calzada del Hueso 1100, Mexico City, 04960, Mexico; E-mail:msperez@correo.xoc.uam.mx

Plants produce different metabolites to ward off animals and microorganisms, as well as to attract pollinators. These metabolites are responsible for the fragrances, colours and toxicity of plants. The plants used in traditional medicines are a good source for the discovery of innovative drugs, as these plants often contain natural products with therapeutic properties, such as antiviral, anti-inflammatory, antimicrobial, antitumor and analgesic effects.

Starting from the purification of morphine in the nineteenth century, up to present day, many additional active plant metabolites have been isolated, including terpenoids, phenolics, flavonoids, alkaloids, *etc.*, [4], leading to the discovery of drugs such as codeine, quinine, paclitaxel and vincristine. Over the last 20 years, one-third of the drugs approved by the Food and Drug Administration (FDA) has been based on natural products or their semi-synthetic derivatives [5], a fact which further indicates the utility of natural products in drug discovery.

The biological activities of plant extracts often involve synergistic effects from the simultaneous action of several components [6]; for this reason, in some cases, the single compound is less effective than the extract. Therefore, research aimed at plant-based drug discovery must draw on novel technologies, such as computational biology methods and quantum computing.

*Bixa orellana* has been used in traditional medicine to treat a variety of health needs. All parts of the plant are used for various reasons, comprising the dried pulp of the fruit, the seeds, the leaves and the roots.

*B. orellana* belongs to the Bixaceae family, commonly known as “Achiote”, and is a shrub or small tree that grows up to 6 m high. This plant is native to Central and South America, but is also cultivated in Southeastern Asia and East Africa. *B. orellana* was named in honour of the Spanish conquistador Francisco Orellana who first explored the Amazon river [7]. The fruits of the shrub are found at the end of the branches, and a fruit contains between 10 to 50 small seeds. Through transmission and scanning electron microscopy, it has been determined that the secretory process of the pigment glands in the vegetative and reproductive organs of *B. orellana* has characteristics such as anastomosed articulated laticifers that produce the reddish latex, rich in carotenoids [8]. The seeds are covered with a thin bright crimson layer; the extract obtained from these outer layers is a colouring agent named annatto, which is widely used in the food, cosmetic and pharmaceutical industries. Additionally, many countries have permitted the use of annatto as a condiment, as well as a food additive for colouring [9]. Thus, the seeds of *B. orellana* are a part of the plant that has commercial importance. Annatto is obtained from the pericarp, which is treated with hot water or steam and then extracted with vegetable oil, chemical bases or supercritical CO<sub>2</sub> [10].

## USE IN TRADITIONAL MEDICINE

Table 1 shows all the parts of *B. orellana* that have been used for many years in different countries, especially South America, Mexico and the Caribbean, for the treatment of diabetes mellitus, constipation, hypertension, infections, mild indigestion, fevers, skin problems and dysentery. This plant has also been used as an aphrodisiac, insect repellent and snake antivenom.

**Table 1. Traditional uses of *B. orellana*.**

Country	Plant Part	Uses	References
Argentina	Seeds	Antidiarrheal, cardiogenic, antipyretic	[11]
Brazil	Leaves	Relief from heartburn, indigestión, antipyretic, antimalaria, laxatives, chemopreventive of cancer	[12 - 14]
Colombia	Leaves and Seeds Roots	Antivenin for snakebites, aphrodisiac, expectorant digestive	[15 - 16]
Cuba	Seeds	Aphrodisiac	[17]
Guatemala	Leaves Roots	Hepatitis, gonorrhoea, dysentery To treat Diabetes mellitus	[18 - 19]
Honduras	Leaves	Dysentery, digestive, analgesic	[20]
Jamaica	Seeds	To treat diabetes mellitus	[21 - 22]
Malaysia	Leaves	Postpartum medicine, treatment of gastric ulcers	[23 - 25]
Nicaragua	Leaves Seeds	Diuretic, antidiarrheal, respiratory diseases, analgesic	[26]
Peru	Leaves Fruits Seeds Roots	Anti-inflammatory, antipyretic, skin problems, to treat indigestion For epilepsy, aphrodisiac, diuretic Astringent, hepatitis	[12 - 16]
Trinidad and Tobago	Leaves Roots Inside of Pods	Diuretic Diabetes Treatment of mange in dogs	[27 - 29]

The objectives of the present review are to present the phytochemistry and pharmaceutical studies of *B. orellana* conducted in the last ten years and to suggest that this plant has potential as a source of pharmacologically active compounds.

## PHYTOCHEMISTRY

From all the different parts of this plant species, a wide variety of compounds have been isolated: mainly carotenes, such as bixin, norbixin, lutein,

## CHAPTER 4

## Overview of Phytochemistry and Pharmacology of Nilakanthi (*Ajuga bracteosa* Wall. ex Benth.)

Apurba Gohain<sup>1</sup>, Debanga Sourav Saikia<sup>1</sup>, Sangita Baruah<sup>2</sup>, Ashoke Kumar Das<sup>3</sup> and Ajay Sharma<sup>4,\*</sup>

<sup>1</sup> Department of Chemistry, Assam University Silchar, Dorgakona, Silchar, Assam, India

<sup>2</sup> Department of Botany, Nowgong College, Nagaon, Assam, India

<sup>3</sup> Department of Botany, Abhayapuri College, Abhayapuri, Srijangram, Assam, India

<sup>4</sup> Department of Chemistry, Chandigarh University, NH-95, Chandigarh- Ludhiana Highway, Gharuan, Mohali, Punjab, India

**Abstract:** Human beings from prehistoric period are mainly dependent on mother nature for the fulfilment of their elementary needs, such as medicines, foodstuffs, shelters, clothing, flavors and fragrances, *etc.* From ancient times, medicinal plants are known to act as a source of a variety therapeutic agents which are widely used in traditional medicine system to cure the various deteriorative diseases and ailments. The wide range of therapeutic applications of various medicinal plants is largely attributed to the presence of a variety of bioactive secondary metabolites (SMs), such as alkaloids, terpenoids, steroids, flavonoids, polyphenolic acids, saponins, tannins, glycosides and essential oils *etc.* Apart from a variety of traditional uses, medicinal plants are also well known for their notable pharmacological potential like anticancer, antiperiodic, antimicrobial, analgesic, antiemetic, antitumor, antioxidant, anti-inflammatory, antiarthritic, *etc.* *Ajuga bracteosa* Wall. ex Benth (*A. bracteosa*), commonly known as Nilakanthi in Ayurveda belongs to the family Lamiaceae, is an important endangered medicinal plant of Himalayan origin. *A. bracteosa* is a good source of flavanol, glycosides, ergosterol, neo-clerodane diterpenoids, iridoid glycosides, 8-endoperoxide and phyto-ecdysones, which shows numerous biological and pharmacological activities *viz.* antiviral, antitumor, antimicrobial, antiplasmodial, anti-inflammatory, antiarthritic, antioxidant, *etc.* Further, variety of *A. bracteosa* leaves uses had been elaborately described in Ayurveda, Unani and Chinese medicine text, for the treatment of numerous ailments like agues, dysentery, vomiting *etc.* The plant is also known for its antivenom potential against snake bite. *A. bracteosa* is an endangered and medicinally high valued Himalayan species that why it is very significant to reveal its full potency. Therefore, the present article mainly focuses on the distribution, cultivation, traditional uses, phytochemistry, pharmacological potential and future prospective of this versatile Himalayan plant.


\* **Corresponding author Ajay Sharma:** Department of Chemistry, Chandigarh University, NH-95, Chandigarh- Ludhiana Highway, Gharuan, Mohali, Punjab, India; Tel: +91-8283000481; E-mails: ajaye7631@cumail.in, sharmaajay9981@gmail.com

Atta-ur-Rahman, FRS (Ed.)

All rights reserved-© 2021 Bentham Science Publishers

**Keywords:** *Ajuga bracteosa*, Himalayas, Medicinal plant, Pharmacology, Phytochemistry, Secondary metabolites, Traditional uses.

## GRAPHICAL ABSTRACT



## INTRODUCTION

The usage of medicinal herbs for the treatment of illnesses is as old as human history and is in vogue since ancient times [1]. It is assumed that about 25-30% of all modern day drugs are natural product derived either directly or indirectly [2]. Though the medicinal plants are distributed worldwide but they are more abundant in tropical areas due to the more favorable environmental conditions. Medicinal plants contain a variety of bioactive compounds with different chemical structures; as a result, they show different modes of action in the biological system. Therefore, single plant extracts or combination of different plant extracts hold great opportunity for the discovery of novel medicine against various human diseases [3]. Medicinal plants (rich in various secondary metabolites (SMs), sources of achiral systems to develop modern medicines, nutraceuticals, food supplements and traditional medicines) naturally synthesize and contain biologically active SMs, like alkaloids, quinines, flavonoids, sterols, terpenes, anthraquinones, glycosides, tannins, saponins, resins, lactones, volatile oils *etc.* Such important bioactive leads are extracted and used in numerous ways, such as injections, syrups, concoctions, decoctions, essential oils, ointments,

infused oil and creams, throughout people's daily lives. Traditional sources of knowledge in medicine such as Ayurveda, Unani, homoeopathy, natural pathology and Siddha are as old as the human origin that is reported to be popular with more than 2/3 of the world's primary healthcare population, especially in developing countries (World Health Organization~ 80%) [4, 5]. The SMs present in the plants are also used in modern clinical studies such as hemorrhoids, osteoporosis, memory loss, cancer, AIDS, malaria, *etc.* because of their long biogenic action in the biological system [6].

There are many families of flowering plants belonging to the Himalayan region, which have high medicinal values. Among them, **Lamiaceae** is the most important family used for medicinal purposes. It is commonly known as the mint or deadnettle or sage family. Plants belonging to this family are mainly aromatic in nature and easy to cultivate through the vegetative propagation method. The family contains 236 genera and 6,900-7,200 species worldwide, which are mainly used for food, ornamental, perfumes and dyes and also used in medicinal purposes [7]. The geographical distribution of this family is from the Mediterranean region to central Asia, also found in tropical and temperate regions. Out of 236 genera, *Ajuga* is the most studied genus due to its high medicinal value. This genus is native to Central Asia, and Eastern Himalayan region to North East India [8].

*A. bracteosa* Wall. ex Benth. is an evergreen perennial growing up to 0.2 m tall, is chiefly found in Eastern Asia to Himalayan region from Kashmir to Nepal and China, also in the wide tropical belt of Assam. The plant is regarded as a high valued medicinal herb in the traditional Chinese, Nepalese and Indian medicine systems. Research conducted on *A. bracteosa* over the last few decades implies the presence of many novel components that have notable bio activity such as anti-viral, anti-depressant, antiplasmodial, diuretic activity, *etc.* Recent studies revealed that *ex-situ* conservation of many wild plants is ignored. Lack of awareness and mismanagement by the people leads to the extinction of many important species causing problems in sustainable cultivation and use [9]. Many literatures reported about its threatened status and declared it as an endangered species by following the guidelines provided by the International Union for Conservation of Nature (IUCN) [10]. Among the various threatened causes, overexploitation by the local people and land degradation are of great concern. Due to its high medicinal properties, it is important to cultivate this plant by traditional and modern biotechnological methods for its conservation [11]. It is recommended to follow a multidimensional approach to select better quality genotype and *ex-situ* as well as *in-situ* conservation techniques [12]. The main objective of this chapter is to provide a brief summary and detailed study on traditional uses, phytochemistry, pharmacology, toxicology of *A. bracteosa*. This chapter also addressed the theoretically advantageous way in the immediate future



## Tetracyclic Benzocarbazoles and Derivatives: Synthesis and Applications

Francisco Vilaça Gaspar<sup>1</sup>, Joseane Alves Mendes<sup>2</sup>, Paulo Roberto Ribeiro Costa<sup>1</sup>, Miguel Yus<sup>2</sup>, Francisco Foubelo<sup>1</sup> and Camilla Djenne Buarque<sup>3,\*</sup>

<sup>1</sup> Laboratory of Bioorganic Chemistry, Nucleus of Research of Natural Products, Health Science Center, Federal University of Rio de Janeiro UFRJ, CEP 21941-590, Rio de Janeiro, Brazil

<sup>2</sup> Departamento de Química Orgânica, Instituto de Síntese Orgânica, and Centro de Innovación en Química Avanzada (ORFEO<sup>+</sup>-CINQA), Universidad de Alicante, Apdo. 99, 03080 Alicante, Brazil

<sup>3</sup> Department of Chemistry, Pontifical Catholic University of Rio de Janeiro Puc-Rio, CEP 22435-900 Rio de Janeiro, Brazil

**Abstract:** Tetracyclic benzocarbazoles are examples of nitrogen-containing heterocycles, which display interesting pharmacological activities and physicochemical properties. This chapter aims to bring some examples about the synthesis of bezocarbazoles, mostly benzo[a]carbazoles (including the dihydro and tetrahydro derivatives), with interesting properties. This chapter also includes aza-pterocarpan and aza-coumestans, which are structurally similar to benzo [a] carbazoles, although their analogous natural products are formed through different biosynthetic pathways. Being aware of the potential interest of these compounds, many efforts have been made for the development of new methodologies to carry out their synthesis and will be discussed below.

**Keywords:** Azaarylation, Aza-coumestans, Aza-pterocarpan, Azaspirodecane, Benzocarbazoles, Chromanones, Chromene, Dihydronaphthalene, Fischer indol, Harmicine, Indole, *N-tert*-butanesulfinyl imine, Tetralone.

### INTRODUCTION

Indole alkaloids occur widespread in many natural products ranging from fungus as psilocybin mushrooms and *Claviceps purpurea* to plants as *Rauwolfia serpentina*, and *Robinia pseudoacacia* [1 - 3]. When the indole system is fused with a naphthalene moiety, it is denominated benzo [a] carbazoles, benzo [b] carbazoles, or benzo [c] carbazoles, depending on the position of the fused rings.

\* Corresponding author Camilla Djenne Buarque: Department of Chemistry, Pontifical Catholic University of Rio de Janeiro Puc-Rio, CEP 22435-900 Rio de Janeiro, Brazil; E-mail: camilla-buarque@puc-rio.br

Benzocarbazoles (BCs) are part of an indoline carboline system and are scarcely found in natural products. The synthetic compounds frequently present a variety of biological activities [4 - 13] and are present in functional organic materials [14 - 16]. Benzo [*a*] carbazoles **1**, dihydrobenzo [*a*] carbazoles **2** and **3**, tetrahydrobenzo[*a*]carbazoles **4**, aza-pterocarpan **5**, and aza-coumestan **6** (Fig. 1) are the most significant related examples highlighted in this chapter due to their interesting properties and activities, although they do not present a unified synthetic pathway. Being aware of their importance, many efforts have been made to develop new methods for obtaining them in a cheaper, greener, and more attractive fashion, allowing for different patterns of substitution to be presented, thus modulating their properties [17, 18]. Initially, the first synthetic approach towards the benzo [*a*] carbazoles relied on the Fischer indole reaction [19] and in the last fifty years, several different methods have been published [5, 20, 21]. The present work will comprehensively cover the most pertinent contributions to this research. We regret in advance that some contributions are excluded to maintain a concise format.





Fig. (1). Some important benzo [*a*] carbazole derivatives.

### Early Methodologies and Modern [3, 3]-sigmatropic Rearrangement

In 1883, Fischer's indole synthesis was one of the first approaches towards C2-C3

substituted indoles [22] and was subsequently employed in the synthesis of 1,2,3,4-tetrahydrocarbazoles [17]. One of the first reactions between  $\alpha$ -tetralone or  $\alpha$ -chromanone and phenylhydrazines dates back to 1975 by Popp and Winchester aiming to prepare ellipticine alkaloids analogs [23]. They effectively employed  $\alpha$ -tetralone **7** with phenylhydrazine **8** in glacial acetic acid, obtaining the dihydrobenzocarbazole **9** Scheme 1. Later, a similar methodology was implemented in 1984 by Sharma and Kaur [24]. They reacted benzochromanone **10** with phenylhydrazine **11**, satisfactorily obtaining dihydrochromenoindole **12** Scheme 1. However, the use of chromanones in those conditions is scarcely reported compared to the ones employing tetralones, probably due to the chemical challenge in the preparation of functionalized chromanones and their intrinsic instability in acidic conditions. Nevertheless, this methodology is one of the best routes for obtaining polyoxygenated tetracyclic compounds to date.



**Scheme 1.** First uses of Fischer indole synthesis with  $\alpha$ -tetralone and  $\alpha$ -chromanones.

Angerer and Prekajac described the first study aiming to establish a structure and activity relationship for dihydrobenzo [*a*] carbazoles and tetrahydrobenzo [*a*] carbazoles in 1986 employing Fischer indole methodology Scheme 2. They showed that dihydrobenzo [*a*] carbazoles **17** and benzo [*a*] carbazoles **18** substituted by hydroxyl groups at the A and D rings displayed estrogen receptor

**CHAPTER 6****Chalcones as Anti-inflammatory, Anti-diabetic, and Anti-depressant Agents****Begum Evranos Aksoz<sup>1,\*</sup>**<sup>1</sup> *Suleyman Demirel University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 32000, Isparta, Turkey*

**Abstract:** Flavonoids are naturally sourced compounds found in many substances consumed as food and have beneficial effects on human health. Chalcones, essential members of the flavonoid family, have also attracted many researchers' attention due to their wide range of pharmacological effects. In this chapter, the antiinflammatory, antidiabetic, and antidepressant activities of the natural compounds in the structure of chalcones and the compounds synthesized with the help these compounds will be discussed. It has been written after a literature review of the articles published between 2000 and 2020 and aims to be a guide for designing new active drug ingredients.

**Keywords:** Aldose reductase, Alpha glucosidase, Antidepressant, Antidiabetic, Antiinflammatory, Butein, Chalcones, Cyclooxygenase, Dipeptidyl peptidase-IV, Heme oxygenase-1, Interleukins, Isoliquiritigenin, Kinases, 5-Lipoxygenase, Monoamine oxidase, Noradrenalin, Protein tyrosine phosphatase 1B, Serotonin, Sodium-glucose cotransporter 2, Tumour necrosis factor-alpha.

**INTRODUCTION**

Diabetes and depression are diseases increasing in frequency with each passing day [1, 2]. While untreated diabetes can cause organ loss and death [3], untreated depression can significantly reduce both quality of life and work performance initially and may result in suicide at a later stage [4].

The incidence of depression and depressive symptoms is twice as high in patients with type 2 diabetes, and the mortality rate is higher than in the general population. Some inflammatory markers, such as interleukin (IL)-1 $\beta$ , IL-1

\* **Corresponding author Begum Evranos Aksoz:** Suleyman Demirel University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 32000, Isparta, Turkey; Tel: +90 246 211 03 44; Fax: +90 246 237 03 30; E-mails: begumevranos@gmail.com and begumaksoz@sdu.edu.tr

receptor antagonist (IL-1RA), monocyte chemoattractant protein (MCP-1), and triglyceride (TG), increase in depression [5]. Inflammation is related to diabetes. Overproduction of an inflammatory mediator, tumour necrosis factor-alpha (TNF- $\alpha$ ), enhances insulin resistance and beta-cell death in pancreatic islets [6]. Inflammation plays a role in the pathogenesis of depression [5, 7] and diabetes [6]. Treatment with antiinflammatory drugs causes antidepressant effects [8], whereas some antidiabetic drugs show antiinflammatory effects [1]. The treatment of these three diseases may be interrelated.

Chalcones, members of the flavonoid family, found in many natural products, draw attention due to their easy synthesis and many pharmacological effects. Chalcones have antiinflammatory [9], antidiabetic [10], and antidepressant activities [11]. When the relationship between inflammation, diabetes, and depression is studied in more detail, chalcones containing these three effects can be a ray of hope in treating these three diseases.

This chapter presents natural and synthetic chalcones with antiinflammatory, antidiabetic, and antidepressant activities and the targets of these compounds while showing their effects.

## **ANTI-INFLAMMATORY CHALCONES**

Inflammation is the immune system's response to infection and injury. Cells of the immune system move to the infection/injury area to repair tissue and heal the wound. Firstly, mediator molecules are released from injured tissue. Thus, it is ensured that the protective and healing components reach the damaged tissue. After that, either the disease can be treated and the stimuli are cleared, or the disease may progress [12]. If the condition continues to advance, chronic inflammation occurs. Excessive amounts of superoxide radicals, proteases, chemokines, and cytokines continue to be released due to periodic signals in chronic inflammation, which can cause subsequent tissue damage [13]. Reducing inflammatory mediators in the macrophages is a critical treatment approach for inflammation.

### **Anti-inflammatory Targets for Chalcones**

Chalcones exert their anti-inflammatory effects by acting on different parts of inflammatory mechanisms. They exhibit their effects through different targets, such as an enzyme, a gene, a receptor, or a chemical released in inflammation. Some targets for chalcones are as follows:

### ***Heme Oxygenase-1***

The anti-inflammatory activity of heme oxygenase-1 (HO-1) is related to its activity in mononuclear phagocytes (monocytes and macrophages) and endothelial cells. Macrophages are activated by cytokines or products of microorganisms and provide the first immune response. Thus activated macrophages initiate the inflammatory response [14]. The induction of HO-1 in macrophages transforms these cells into anti-inflammatory phenotypes [15]. HO-1 inhibits adhesion molecule expression, decreases oxidative stress, and protects the cell from inflammation [16].

### ***Nuclear Factor- $\kappa$ B and Histone Deacetylases***

Nuclear factor  $\kappa$ B (NF- $\kappa$ B) is a transcription factor that controls the release of iNOS and cytokines, such as TNF- $\alpha$  and IL-1 $\beta$ , and is found in macrophages [17]. It is a dimer that is composed of two similar subunits. NF- $\kappa$ B is mainly found complexed with the inhibitory molecules of the inhibitory kappa B (I $\kappa$ B) family. I $\kappa$ B proteins must be degraded for NF- $\kappa$ B to be activated after a stimulus. Phosphorylation of I $\kappa$ B molecules is necessary for this degradation [18]. NF- $\kappa$ B inhibition is an important target to stop the release of proinflammatory mediators.

Histone deacetylases (HDACs) are enzymes that remove the acetyl group from lysine and impact inflammatory gene expression [19]. Since the NF- $\kappa$ B pathway is a significant adjuster of the expression of many inflammatory genes, acetylation plays a vital role in adjusting many responses of NF- $\kappa$ B. Histone deacetylases play a role in regulating the NF- $\kappa$ B signalling pathway, therefore, inhibitors of HDACs are targets for decreasing the inflammatory response [20].

### ***Kinases and Activator Protein-1***

Kinases are enzymes that transfer phosphate groups from high-energy donor molecules, such as ATP, to particular substrates *via* phosphorylation [13]. The main pathway that controls the part of inflammation involved in gene expression is the activation of the NF- $\kappa$ B. Mitogen-activated protein kinases (MAPKs) are responsible for the expression of pro-inflammatory cytokines, such as interleukin-1 and TNF [21]. The c-Jun amino-terminal kinases (JNKs) are a group of MAP kinases [22]. I $\kappa$ B kinases (IKKs) play a critical role in regulating the NF- $\kappa$ B cascade [23]. Activator protein-1 (AP-1) is a transcription factor that induces pro-inflammatory cytokine expression [24].

## Bioactive Steroids from Marine Organisms

Marina P. Savić<sup>1,\*</sup>, Marija N. Sakač<sup>1</sup> and Jovana. J. Ajduković<sup>1</sup>

<sup>1</sup> Department of Chemistry, Biochemistry and Environmental Protection, Faculty of Sciences, University of Novi Sad, Trg Dositeja Obradovića 3, 21000 Novi Sad, Serbia

**Abstract:** Natural products have played a key role in cancer drug discovery, as well in other therapeutic fields. In the past decades, marine organisms have proven to be a primary source of new potentially bioactive natural products for drug discovery. By reviewing the literature describing marine organisms and isolated metabolites, we can notice a large increase in the number of studies today compared to the end of the 20<sup>th</sup> century. The number of structures isolated each year has almost doubled over the past 20 years. Because of their topicality, we have focused on natural bioactive steroids isolated from marine organisms. In the chapter ‘Bioactive Steroids from Marine Organisms’, an overview of the new steroid compounds isolated from marine sponges, macroalgae and cucumbers, described in the relevant literature in the period from 2011 to 2020, is given. To provide a comprehensive introduction in the field of marine bioactive steroids, we highlighted typical molecules grouped according to their structural characteristics with additional reference to their biological activity. The structures of the new compounds, their natural origin (species of the organism) and their rich biological activities are presented and described in detail. In addition, biological tests performed on known compounds during this time period are also described. Some of the compounds possess multiple activities and have been tested only in a limited number of biological assays, which means that the full potential and significance of these compounds may only be discovered in the future.

**Keywords:** Bioactivity, Biosynthetic origin, Marine cucumber, Marine macroalgae, Marine sponges, Natural steroids, Structural characterization.

### INTRODUCTION


The American, Werner Bergmann, was one of the first scientists who started the chemical investigation of marine organisms. He reported the isolation of unusual nucleosides from the sponge *Cryptotethia crypta* collected near the coast of Florida [1] and his discovery was followed by the development of the very first marine-derived drug, Cytarabine, which destroys cancer cells by blocking DNA

\* Corresponding author Marina P. Savić: Department of Chemistry, Biochemistry and Environmental Protection, Faculty of Sciences, University of Novi Sad, Trg Dositeja Obradovića 3, 21000 Novi Sad, Serbia; Tel: +381 2148 5273 3; E-mail:marina.savic@dh.uns.ac.rs

polymerase function [2]. In 1969, the U.S. Food and Drug Administration (FDA) approved this drug for the treatment of leukemia. Currently, there are six FDA-approved marine-derived drugs in the market and several compounds in different phases of the clinical trials [3].

Steroids are a major class of natural compounds with an important biological role. They have attracted great attention over the years from medicinal chemists in the search for new drugs. Their function involves the constitution of the membrane, hormonal function, protective functions and many others. Steroid-based compounds are widely used in medicine as drugs with anti-inflammatory, anabolic, contraceptive or anticancer activities [4].

The term ‘steroid’ covers a wide variety of compounds based on a partially cyclized isoprenoid skeleton. These molecules are structurally defined by their 17-carbon tetracyclic (cyclopentanoperhydrophenanthrene) core containing three cyclohexane rings (A, B, and C) and one cyclopentane (D ring). The numbering of the steroid nucleus is presented in the example of a cholestane-type compound, which is structurally the most representative (Fig. 1).



**Fig. (1).** The structure and the numbering of a cholestane-type compound.

The chapter ‘Bioactive Steroids from Marine Organisms’ covers the literature published in the period from 2011 to 2020 relating to the new steroid compounds isolated from marine sponges, macroalgae and cucumbers. The chapter contains three subchapters, each relating to one of the groups of marine organisms. Within these subchapters, steroid compounds are grouped according to their common structural characteristics, while their biological activity is additionally described, as well as their biosynthetic origin. Also, new biological activity for known steroid compounds is described.

## **BIOACTIVE STEROIDS FROM MARINE SPONGES**

The sponges are the simplest and probably oldest group of animals that have separated from other metazoans. They are sessile organisms that do not possess true tissues, organs or nerve structures [5]. Sponges are important within the fields



of marine biotechnology and marine pharmacology. They are considered the best resources for highly active therapeutic molecules amongst other marine invertebrates.

Marine sponges are the source of a large number of compounds with unusual carbon frameworks and functionalities. Various compounds with a unique structure, such as secosteroids or steroids with sugar moiety on the side chains of steroid compounds, are often present [6, 7].

In the literature, novel compounds, particularly steroids with a diverse range of conventional and unconventional side chains and nuclei with various biological activities have been described as secondary metabolites of sea sponges [8]. Due to their significant potential, steroid compounds isolated from sponges will be described in this subchapter.

### A-Norsteroids

A-Norsteroids are a class of steroids with unusual A-nor skeleton, in which carbon was biosynthetically or synthetically removed from the A-ring of steroid compound. Such unusual compounds have also been isolated from sponges and described in the literature (Fig. 2) [9, 10].




Fig. (2). A-Norsteroids.

Ragini *et al.* [9] have isolated two new steroids, crellasterones A (1) and B (2) (Fig. 2), with the previously reported compounds from the sponge *Crella incrustans*, collected in New Caledonia. The structures of the new compounds revealed unprecedented marine natural products with a ring-contracted A-norsterone nucleus and 2-hydroxycyclopentenone chromophore. Crellasterones A (1) and B (2) have an identical steroid skeleton, but differ in the side chain at the

**SUBJECT INDEX****A**

- Acanthifoliosides 273, 274  
Acetyl-CoA carboxylase (ACC) 77, 257  
Acid 19, 15, 35, 37, 39, 41, 46, 119, 124, 125,  
126, 127, 146, 171, 174, 176, 178, 179,  
119, 185, 200, 211, 216, 273  
alpha-linolenic 19  
arachidonic 200  
arjunolic 119  
ascorbic 127, 216  
boronic 174  
bractic 146  
carboxylic 35, 37, 46, 273  
chiral phosphoric 178, 179  
deoxyribonucleic 125  
glucuronic 273  
homocysteic 185  
hydrolysis 39, 41  
Lewis 171  
maslinic 119  
nordihydroguaiaretic 211  
nucleic 124  
oleanolic 286  
peripheral D-amino 66  
polyphenolic 139  
polyunsaturated fatty 124, 200  
thiobarbituric 126, 127  
tiglic 15  
trifluoroacetic 176  
ursolic 119  
Acquired immunodeficiency syndrome 32  
Activation 119, 126  
persistent immune 119  
signalling pathway 126  
Activity 39, 41, 46, 58, 60, 65, 114, 118, 119,  
123, 124, 129, 141, 145, 146, 151, 166,  
202, 206, 216, 219, 223, 224, 225, 227,  
228, 231, 234, 255, 273, 274, 282, 295,  
297, 301  
anti-Alzheimer 227  
anti-arthritic 145  
anticholinesterase 206  
anticoagulant 145, 151  
antidiabetic 219, 223  
antigenotoxic 129  
anti-HIV 60  
antileukemic 166  
antimelanoma 123  
antimycobacterial 151, 255  
antiparasitic 118, 119  
antiretroviral 41  
antitrypanosomal 255  
diuretic 141  
estrogenic 282  
immunomodulatory 297  
leishmanicidal 274  
lysosomal 297  
membranolytic 301  
microbicidal 114  
neuroprotective 228  
trypanocidal 273  
Acyl carrier protein (ACP) 74, 75  
Adenosine monophosphate activated protein  
kinase 217  
Agents, anti-HIV 60, 61, 72  
Aglycone 301, 304  
oxidized holostane 301  
possessing 304  
AIDS pandemic 60  
Alanine aminotransferase 128  
Aldose reductase (AR) 197, 218, 219, 221,  
223, 262, 287, 291  
inhibitory activity 219  
Alkaline phosphatase 128  
Alzheimer's disease 146, 252  
Ameliorated cardiac dysfunction 126  
Amino acid 35, 37, 39, 41, 45, 46, 49, 51, 77  
non-proteinogenic 37  
proteinogenic 37  
Analgesic activities 145, 214, 215, 229, 230  
Angiogenesis 146  
Annato hydroalcoholic extract 116

## Subject Index

Antibacterial activity 51, 63, 250, 265, 266, 289, 311  
Antibiotics 31, 55, 74, 114, 283  
  benanomycin-pradimicin 31  
Anticancer activities 5, 11, 12, 13, 19, 248, 310  
Anticancer agents 1, 4, 20, 51, 120, 306  
  plant-derived 1, 20  
Anticancer chemotherapeutic drugs 4  
Antidepressant 145, 197, 198, 226, 227, 228, 230, 232, 233, 234, 235  
  activities 145, 197, 198, 226, 227, 228, 230, 232, 233, 234  
  effects 198, 226, 227, 233, 234, 235  
  targets for chalcones 226  
Antidiabetic 217, 219, 221, 222, 223  
  activity 219, 221, 222, 223  
  chalcones 217  
  properties 217  
Antidiabetic targets for chalcones 217  
Antifungal 32, 37, 38, 40, 46, 48, 50, 51, 57, 58, 59, 64, 65, 250, 287, 293  
  activity 37, 38, 40, 46, 48, 50, 51, 57, 58, 59, 64, 65, 250, 287, 293  
  drugs 32  
Antihyperglycaemic activity 224  
Anti-inflammatory 119, 120, 150, 198, 202, 203, 205, 206, 207, 208, 209, 210, 211, 213, 214, 215, 216  
  action 150  
  activity 119, 120, 202, 203, 205, 206, 207, 208, 209, 210, 211, 213, 214, 215, 216  
  agent 207  
  chalcones 198  
Anti-inflammatory effects 119, 120, 198, 204, 206, 208, 213, 214, 226, 234  
Antimalarial properties 15, 119  
Antimicrobial 110, 114, 118, 129, 151, 211, 251, 258, 268, 273  
  activity 110, 114, 129, 151, 211, 251, 258, 268  
  bioassays 273  
  photodynamic therapy 118  
  resistance 114  
Antimutagenic property 149  
Antineoplastic 165, 180  
  action 165  
  activity 180  
Antioxidant 13, 110, 124, 126, 127, 205, 211, 212, 213, 214, 216, 292

## Frontiers in Natural Product Chemistry, Vol. 7 331

  activities 13, 110, 124, 126, 127, 205, 211, 212, 213, 216, 292  
  agents 214  
  enzymes 126  
Anti-Parkinson activity 311  
Antiplasmodial activity 145, 285  
Antiproliferative 12, 166, 167, 251, 269  
  activity 166, 167, 251  
  effects 12, 123, 269  
Apoptosis 12, 14, 19, 72, 73, 146, 211, 278  
  inducing 278  
  mitochondrial 19  
  tumor 12, 14  
Arachidonic acid metabolism pathways 201  
Arachis oil 129  
Aromatic polyketides 31, 35, 36, 74  
Aspartate transaminase 128  
Aspergillosis 57, 59  
  invasive pulmonary 59  
*Aspergillus* 58, 116, 291, 295, 297  
  *fumigatus* 58  
  *niger* 116, 291, 295, 297  
Assays 68, 125, 149, 216, 256, 260  
  chemiluminescence 125  
  cytotoxicity 260  
  radical scavenging 216  
Ayurvedic 4, 5, 6  
  medicine 4  
  plants 5, 6  
  system of medicine in cancer therapies 4

## B

*Bacillus* 115, 151, 251, 266, 267  
  *cereus* 115, 151  
  *licheniformis* 267  
  *subtilis* 114, 151, 251, 266  
Benanomycin-pradimicin antibiotics (BPAs)  
  31, 32, 34, 37, 39, 51, 54, 57, 60, 62, 63, 64, 65, 66, 68, 69, 71, 73, 74, 94  
Benzyl amino purine (BAP) 144  
Bioactive Steroids of marine biotechnology 249  
Blood glucose 217, 218, 222, 223  
Bracteosa plant 150  
Brain dysfunctions 144  
Breast 8, 9, 284  
  adenocarcinoma 284  
  and colon cancers 8, 9

**C**

Calcium-dependent Mannose binding 64  
Cambridge crystallographic data centre (CCDC) 69  
Cancer research 1  
Cancers 2, 3, 7, 18, 19, 123, 253, 287  
  brain 3  
  cervical 2, 253  
  colorectal 7, 123  
  human pancreatic 287  
  liver 18  
  lung 2, 18  
  mammary gland 19  
  ovarian 8, 9, 18, 287  
  testicular 18  
Cancer therapy 3, 12, 125  
*Candida albicans* 117, 251, 258, 265, 298  
Carbohydrate-binding 31, 71, 72  
  agents (CBAs) 31, 71, 72  
  proteins (CBPs) 72  
Carboxylase 77  
Carcinogenesis 20  
Cardiovascular conditions 4  
Catenin response transcription (CRT) 269  
Cellular 217, 223  
  energy homeostasis 217  
  glucose uptake activity 223  
Chemical transformations 89  
Chromatography 34, 149  
  silica gel column 149  
Cisplatin-induced DNA damage 124  
Colon 4, 6, 8, 9, 10, 18, 123, 165, 284  
  cancer 4, 6, 8, 9, 10, 18, 123, 165  
  carcinoma 284  
Cryptococcosis 57  
Cytokine expression 199, 202, 213  
  anti-inflammatory 202  
  pro-inflammatory 199  
Cytotoxic 17, 123, 124, 202, 207, 208, 213, 258, 259, 260, 272, 278, 283, 284, 287, 288, 296, 297, 298, 304, 305  
  activities 123, 124, 207, 208, 258, 260, 272, 284, 287, 288, 296, 297, 298, 304, 305  
  agents 283  
  assay 213  
  effects 17, 123, 202, 259, 278, 284

**D**

Damage, cisplatin-induced genotoxic 124  
Depression 197, 198, 226, 227, 229, 234  
Derivatives, rare non-holostane 301  
Diabetes 112, 121, 217, 218, 219, 234  
  mellitus 112, 121, 217, 218  
  treatment 217, 218, 219, 234  
Diabetic cardiomyopathy 120  
Diet, vegetable-rich 20  
Diseases 3, 4, 110, 112, 119, 120, 121, 122, 125, 129, 144, 145, 150, 151, 197, 198, 234, 285, 292  
  bladder 145  
  cardiovascular 144  
  heart 150  
  infectious 151  
  metabolic 121  
  neurological 234  
  oxidative stress-related 285  
  respiratory 112  
Disorder 152, 217, 226  
  cardiovascular 152  
  chronic metabolic 217  
Display proinflammatory 202  
DNA 2, 12  
  repair mechanisms 2  
  topoisomerase 12  
Drugs 4, 20, 61, 72, 111, 123, 129, 140, 198, 217, 248, 260  
  antiinflammatory 198

**E**

Echavarren's catalyst 175, 176  
Effects 13, 16, 61, 65, 198, 219, 224, 234, 285, 306  
  antagonistic 65  
  antiapoptotic 224  
  antibacterial 306  
  anticancer 16  
  antidiabetic 219, 234  
  antiinflammatory 198  
  chemotherapeutic 13  
  cytopathic 61  
  cytoprotective 285  
Ehrlich carcinoma cells 272, 295, 296, 297, 300, 303, 304, 306, 308  
  cells and hemolysis 272

## Subject Index

Eisenia bicyclis 284  
Elastase release 290  
Electrical conductivity 127  
Electrolytes 129  
Electroshock 285  
Enzymes 48, 74, 75, 76, 77, 78, 123, 124, 146, 198, 199, 200, 204, 217, 218, 226, 227, 234  
    histone deacetylase 204  
    lipoxygenase 146  
    methyltransferase 48  
    monoamine oxidase 234  
Evidence-based medicine (EBM) 6  
Expression, mRNA 213, 253  
Extracellular signal-regulated kinase 202

## F

Farnesoid-X-receptor (FXR) 277, 280  
Fatty acid 19  
    synthase signaling 19  
    synthesis 19  
FDA-approved marine-derived drugs 248  
Feline immunodeficiency virus (FIV) 62  
Ferric-reducing antioxidant power (FRAP) 126, 127  
Fibroblast collagenase 284  
Fischer's indole synthesis 159  
Flavin adenine dinucleotide (FAD) 231, 232  
Flavonoids possess 11  
Food and drug administration (FDA) 3, 62, 111, 248  
Food  
    preservatives 144, 305, 306  
    supplements 140  
Fungal infections 57  
*Fusarium oxysporum* 289, 295

## G

Gastric 112, 305  
    cancer cell 305  
    ulcers 112  
Gene therapy 2, 3  
Glucose 217, 218, 219, 222, 287  
    metabolism 218, 287  
    reabsorption, renal 219  
    tolerance 222  
    transport 222

## Frontiers in Natural Product Chemistry, Vol. 7 333

    transportation 217  
Green synthesis 151  
Griess assay 206  
Growth 64, 210  
    tumour 64  
    vascular 120  
Growth inhibition 251

## H

Haematopoiesis 202  
Heart attacks 217  
Hemolytic activity 293, 295, 296, 297, 298, 300, 301, 305, 307, 308, 311  
Hepatitis C virus (HCV) 62, 150  
Hepatocellular carcinoma cells (HCC) 124  
Hepatoprotective activity 128  
Hesperidin methyl chalcone (HMC) 207, 211  
Hexokinase pathway 218  
Histone 199, 209, 210, 278  
    acetyltransferase 278  
    deacetylases 199, 209, 210  
HIV infection 60, 62, 71, 72  
Hodgkin's lymphoma 7  
Human 121, 256, 260, 261, 268, 269, 270  
    cholangiocarcinoma 269  
    colon adenocarcinoma 261, 268  
    hepatocellular carcinoma 256  
    lung adenocarcinoma 260  
    medulloblastoma 270  
    pancreatic amylase (HPA) 121  
Human gastric 7, 18, 258  
    cancer 18  
    carcinoma 7, 258  
Huntington's diseases 144  
Hydrogenolysis 46  
Hyperglycaemia 219, 224  
Hyperglycemia 123  
Hyperlipidaemia 219  
Hypoglycaemic activities 220, 225  
Hypothalamus 228

## I

Immunomodulatory 151, 312  
    activity 312  
    actions 151  
Infections 58, 255  
    genital 255

systemic 58  
Infertility 3  
Inflammasome 121  
Inflammatory disorders 143, 144  
Inhibition 129, 211  
    oxidative stress 129  
    radical 211  
Inhibitory activities 202, 207, 210, 221, 225,  
    231, 251, 263, 269, 287  
    lipoxygenase 210  
Inhibitory effects 60, 202, 253, 260, 283, 285,  
    288, 290, 291  
Insulin 122, 123, 198, 217, 218  
    resistance 122, 123, 198, 217, 218  
    signal transduction 218  
Interleukins 121, 197, 201, 202, 253  
    anti-inflammatory 202  
    proinflammatory 202  
International union for conservation of nature  
    (IUCN) 141  
Iron, chelating 127

## K

Ketosynthase 74  
Key disconnections 89  
Kinase(s) 13, 14, 73, 197, 199, 213, 217, 257  
    activated protein 257  
    activation 213  
    amino-terminal 199  
    enzyme tyrosine 13  
    monophosphate-activated protein 217  
    pathway 73  
    receptor tyrosine 14

## L

Laryngeal cancer 6  
Larynx carcinoma 149  
*Leishmania amazonensis* 119  
Leukemia 3, 7, 8, 9, 11, 15, 18, 19, 180, 248,  
    252, 261, 269  
    acute lymphoblastic 261, 269  
    and colon cancer 8  
    lymphocytic 3, 252  
Lipid 122, 217  
    homeostasis 217  
    metabolism 122  
Liposome permeabilizing activities 274

Lipoxygenase pathway 200  
Liver 128, 292  
    cancer cells 292  
    damage 128  
Low-density lipoproteins (LDL) 125, 128  
Lymphomas, non-Hodgkin 18

## M

Marine 247, 249, 258, 270, 283, 284, 288, 292  
    invertebrates 249, 258, 270, 292  
    macroalgae 247, 283, 284, 288  
Marine sponge 265, 311  
    *Lissodendryx fibrosa* 265  
    *poecillastra* 311  
    polymastia 311  
Medicinal 3, 4, 5, 6, 11, 20, 114, 139, 140,  
    144, 145  
    herbs 5, 114, 140  
    plants 3, 4, 5, 6, 11, 20, 139, 140, 144, 145  
Medicine 4, 5, 6, 20, 71, 110, 111, 112, 139,  
    140, 141, 152, 248, 284, 292  
    ancient Chinese 292  
    traditional 4, 6, 110, 111, 112, 140  
Mediterranean region 141  
Metabolic 121, 122, 123, 124, 129, 217  
    conditions 124  
    disorders 121  
    processes 129  
    syndrome 121, 122, 217  
Metabolism 123  
Methyl ester possess 274  
Microbial cell surface imaging 71  
*Microsporium gypseum* 298  
Minimum 57, 58, 59, 65, 114, 118, 151, 287,  
    293, 294, 297  
    bactericidal concentration (MBC) 114, 118  
    inhibitory concentrations (MIC) 57, 58, 59,  
    65, 114, 118, 151, 287, 293, 294, 297  
Mitochondrial outer membrane  
    permeabilization (MOMP) 12  
Mitogen-activated protein (MAP) 14, 73, 199,  
    203, 210, 213  
    kinase (MAPKs) 14, 199, 203, 210, 213  
Monocyte-derived dendritic cells (MDDC) 63  
MTT assay 123, 124  
*Mycobacterium avium* 251  
*Mycobacterium tuberculosis* 251, 255  
Mycoses 57, 59, 60  
    invasive 57

**N**

Natural killer cells 201  
Natural storage technique 144  
Neurotransmission 120  
Neurotransmitters 226, 227  
Neutralising antibodies 72  
Neutropenia 57  
Nitrene pathway 181  
Nitric oxide synthase 200  
NMR spectroscopy 75  
Non 2, 37  
    invasive medical technique 2  
    ribosomal peptides (NRPs) 37  
Nuclear 34, 66, 68, 70, 199  
    factor- $\kappa$ B and histone deacetylases 199  
    magnetic resonance (NMR) 34, 66, 68, 70

**O**

Open reading frames (ORFs) 74  
ORAC assay 213  
Organ transplantation 57  
Osteoporosis 122, 141  
Osteosarcoma 9, 124  
Oxidative processes 126

**P**

Parapsilosis 39, 306  
Parasitosis 118  
Parkinson's diseases 235, 256, 285  
Pathogens 39, 55, 60, 61, 66, 72, 151, 200, 251, 268, 287  
    mycobacterial 251  
    non-viral 72  
Pathways 2, 4, 12, 14, 19, 20, 73, 78, 226  
    apoptotic 12  
    metabolic 20, 78  
    signaling 2, 12  
Peroxisome proliferator-activated receptors (PPARs) 123, 218  
Pheochromocytoma 124  
Photoredox catalysis 184  
Pictet-Spengler cascade 178  
Plancher rearrangement reaction 172  
Plant-derived 1, 2, 3, 11, 19, 20  
    agents 3  
    anticancer compounds 1, 2, 11, 19, 20

Plant-derived anticancer drugs 17  
Polyhydroxylated steroids 14, 256, 257, 310, 311  
    plant-derived 14  
Polyketide(s) 51, 55, 78, 79, 86  
    backbone, methyl-enriched 51  
    biosynthesis 78  
    fused tetracyclic 86  
Polymerase chain reaction (PCR) 213  
Polyoxygenated steroids 287  
Pradimicin 33, 34, 37, 38, 39, 40, 41, 43, 46, 48, 57, 60, 61, 62, 63, 67, 68, 69, 70, 71, 77, 78  
    biosynthesis of 40, 77, 78  
Pregnane-X-receptor (PXR) 262, 277, 280  
Pro-inflammatory cytokines 199, 201  
Properties 4, 39, 127, 128, 151, 159, 178, 190, 202, 270  
    anti-bacterial 151  
    anticarcinogenic 270  
    anti-inflammatory 4, 202  
    hepatoprotective 128  
    metal ion-chelating 127  
    sedative 178  
Prostate 8, 15, 18, 262  
    cancer 8, 15, 18  
    specific antigen (PSA) 262  
Protein(s) 13, 37, 63, 64, 73, 115, 124, 125, 197, 198, 205, 217, 218, 221, 284  
    glucose transporter 217  
    heat shock 13  
    mitogen-activated 73  
    monocyte chemoattractant 198  
    tyrosine phosphatases (PTPs) 197, 218, 221  
*Pseudomonas aeruginosa* 63, 151  
*Psoralea corylifolia* 205, 210

**R**

Radiation therapy 2  
Rancimat test 126, 127  
Range, high nanomolar 62  
Reaction 80, 82, 84, 89, 119, 126, 163, 164, 168, 169, 171, 173, 174, 175, 176, 178  
    acute inflammatory 119  
    carboamination 175, 176  
    free-radical-mediated chain 126  
    palladium-catalyzed aza-arylation 164  
    palladium-catalyzed coupling 174  
Reactive 12, 73, 121, 125, 126, 207, 253, 285

nitrogen species (RNS) 126  
oxygen species (ROS) 12, 73, 121, 125, 126, 207, 253, 285  
Receptor tyrosine kinase (RTK) 14  
Relative resistance (RR) 166  
Releasing cytokines 207  
Respiratory syncytial virus (RSV) 62  
Response 61, 73, 121, 122, 123, 150, 198, 199, 200, 201, 213, 217, 290  
  antiviral 61  
  dose-dependable anti-inflammatory 150  
  immune system's 198  
  inflammatory 121, 122, 199, 200  
Retinopathy 219, 287  
Reversed-phase columns 34

**S**

*Saccharomyces cerevisiae* 65  
*Salmonella typhi* 115, 151  
Saponification 89  
Secondary metabolites (SMs) 32, 74, 79, 114, 139, 140, 141, 144, 146, 152, 249  
Secosteroids 249, 265, 266, 310, 311  
  synthetic 265  
Semi-preparative HPLC 43  
Silver nanoparticles 151, 152  
  biosynthesized 151  
  green synthesized 151  
Simian immunodeficiency virus (SIV) 61, 62  
Skeletal myoblasts 257, 274  
Skin 2, 18, 285, 292  
  cancer 2, 18  
  photodamage 285  
Spectroscopic techniques 34  
Sponges 248, 249, 251, 252, 253, 257, 258, 261, 262, 266, 270, 274, 279  
  deep-water 251  
Spongosteroids 261  
*Staphylococcus* 63, 115, 151, 251, 258, 265, 266, 267, 289  
  *aureus* 63, 115, 151, 251, 258, 265, 266, 267, 289  
  *epidermidis* 266  
Stereochemistry 37, 46  
Stereoselectivity, high 176, 189  
Stereoselective synthesis 177  
Steroid(s) 114, 115, 248, 249, 250, 254, 257, 258, 261, 262, 282, 283, 284, 285, 288, 293, 295, 309, 310, 311, 312

alkaloids 250, 310, 311  
compounds 248, 249, 282, 293, 295, 309, 310  
glycosides 270, 271, 273, 310, 311, 312  
monosulfates 261, 262  
skeleton structure, identical 258  
*Streptococcus* 63, 151  
  *agalactiae* 63  
  *pyogenes* 151  
Stress 14, 19, 73, 125, 126, 180, 199, 219  
  hyperosmotic 73  
  mitochondrial 19  
  oxidative 73, 125, 126, 180, 199, 219  
Structure-activity relationships (SARs) 42, 47, 54, 55  
Superoxide dismutase activities 19  
Supramolecular 71  
  chemistry 71  
  chemoreceptor 71  
Surface plasmon resonance (SPR) 62, 68  
Swinhoeisterols 278  
Swinhosterols 275, 279  
Symptoms 118, 197, 226, 285  
  depressive 197  
  neuropsychiatric 285  
Synthase 120, 125, 208  
  suppressor activities 208  
Synthesis 90, 152, 169, 179, 181, 182, 183, 184, 185, 187  
  of aza-coumestans 181, 182, 183, 184, 185  
  of benanomicin 90  
  of benzocarbazoles 169, 185, 187  
  of chiral tetrahydro- $\beta$ -carboline 179  
  of metal nanoparticles 152

**T**

Tail suspension test (TST) 226, 227, 232, 233  
Tetrasaccharide 297  
Therapies 1, 3, 5, 18, 20, 123, 260  
  photodynamic 3  
  plant-derived 5  
  systemic 2  
  traditional 1  
Thomosamine 78  
Throats, sore 143, 145, 146  
Thromboxanes 200  
TLC-bioautography 151  
Tocotrienol isomers 115  
Topsensterols 258



## Subject Index

trivial name 258  
Toxicity 17, 18, 61, 111, 124, 125  
  inhibiting cisplatin 125  
Traditional 3, 4, 5, 139  
  Chinese medicine (TCM) 3  
  Indian medicine (TIM) 4, 5  
  medicine system 139  
Transcarboxylase 77  
Transcription 199, 218, 269  
   $\beta$ -catenin response 269  
  factors 199, 218  
Transforming growth factor- $\beta$ 1 284  
Transition metals 127  
Transmission 61, 62, 94, 111, 227  
  prevented HIV 61  
  serotonergic 227  
Transmission electron microscopy 64  
Transport 129  
  mechanisms 129  
  processes 129  
Treatment 1, 3, 4, 5, 6, 20, 34, 59, 60, 62, 112,  
  118, 120, 198, 234  
  antimicrobial 118  
Trichophytosis 57  
Triterpene glycosides 292, 293, 297, 298, 300,  
  302, 305, 306, 308  
  pentasaccharide 308  
  holostane 305  
*Trypanosoma* 63, 255, 274  
  *brucei* 63, 255  
  *cruzi* 274  
Tumor(s) 4, 18  
  prognosis 4  
  solid 4, 18  
Tumor cell(s) 2, 3, 12, 19, 20, 146, 272, 298  
  death 19, 20  
  proliferation 12, 146  
  fast-growing 3

## U

Urinary disorders 145  
Urothelial cancer 18

## V

Vascular 119, 120, 201  
  cell adhesion molecule-1 201  
  permeability 119, 120

## Frontiers in Natural Product Chemistry, Vol. 7 337

Vegetable oil 111  
Vegetative propagation method 141  
Vietnamese marine sponge 260  
Viral pathogens 31, 56, 61, 63, 68  
  glycosylated 68  
Viruses 2, 14, 32, 62, 63, 72, 114, 150  
  dengue 63  
  human immune deficiency 32  
  herpes simplex 62  
  influenza 63  
Visceral leishmaniasis 118

## W

Waals interactions 232  
Water solubility 39, 61  
Weak cytotoxicity 297  
World health organization (WHO) 4, 110, 141

## X

Xenobiotic sensor 262  
*Xestospongia testudinaria* 253, 269, 270, 280,  
  281, 310  
  barrel sponge 269  
  marine sponge 253, 310  
  sponge extracts 280  
x-ray diffraction 167

## Y

Yeast cells 73

## Z

*Zingiber officinale* 5, 8



## **PROF. DR. ATTA-UR-RAHMAN, FRS**

Prof. Atta-ur-Rahman, Ph.D. in Organic Chemistry from Cambridge University (1968) has 1,232 international publications (45 international patents and 341 books). He received the following awards: Fellow Royal Society (FRS) London (2006), UNESCO Science Prize (1999), Honorary Life Fellow Kings College, Cambridge University (2007), Academician (Foreign Member) Chinese Academy of Sciences (2015), Highest Civil Award for Foreigners of China (Friendship Award, 2014), High Civil Award Austria ("Grosse Goldene Ehrenzeischen am Bande") (2007), Foreign Fellow Chinese Chemical Society (2013), Sc.D. Cambridge University (UK) (1987), TWAS (Italy) Prize (2009). He was the President of Network of Academies of Sciences of Islamic Countries (NASIC), Vice President TWAS (Italy), Foreign Fellow Korean Academy of Science & Technology, President Pakistan Academy of Sciences (2003-2006) and (2011 – 2014). He was the Federal Minister for Science and Technology of Pakistan (2000 – 2002), Federal Minister of Education (2002) and Chairman Higher Education Commission/Federal Minister (2002-2008), Coordinator General of COMSTECH (OIC Ministerial Committee) (1996-2012), and the Editor-in-Chief of Current Medicinal Chemistry.